Literature DB >> 22426465

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms.

Olga A H Reneerkens1, Kris Rutten, Sven Akkerman, Arjan Blokland, Christopher L Shaffer, Frank S Menniti, Harry W M Steinbusch, Jos Prickaerts.   

Abstract

A promising target for memory improvement is phosphodiesterase type 5 (PDE5), which selectively hydrolyzes cyclic guanosine monophosphate (cGMP). In rodents, PDE5 inhibitors (PDE5-Is) have been shown to improve memory performance in many behavioral paradigms. However, it is questioned whether the positive effects in animal studies result from PDE5 inhibition in the central nervous system or the periphery. Therefore, we studied the effects of PDE5 inhibition on memory and determined whether compound penetration of the blood-brain barrier (BBB) is required for this activity. Two selective PDE5-Is, vardenafil and UK-343,664, were tested in the object recognition task (ORT) in both a MK-801- and scopolamine-induced memory deficit model, and a time-delay model without pharmacological intervention. Compounds were dosed 30 min before the learning trial of the task. To determine if the PDE5-Is crossed the BBB, their concentrations were determined in plasma and brain tissue collected 30 min after oral administration. Vardenafil improved object recognition memory in all three variants of the ORT. UK-343,664 was ineffective at either preventing MK-801-induced memory disruption or time-dependent memory decay. However, UK-343,664 attenuated the memory impairment of scopolamine. Vardenafil crossed the BBB whereas UK-343,664 did not. Further, co-administration of UK-343,664 and scopolamine did not alter the brain partitioning of either molecule. This suggests that the positive effect of UK-343,664 on scopolamine-induced memory decay might arise from peripheral PDE5 inhibition. The results herein suggest that there may be multiple mechanisms that mediate the efficacy of PDE5 inhibition to improve memory performance in tasks such as the ORT and that these involve PDE5 located both within and outside of the brain. To further elucidate the underlying mechanisms, the cellular and subcellular localization of PDE5 needs to be determined.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426465     DOI: 10.1016/j.nlm.2012.02.008

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  15 in total

1.  Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses.

Authors:  G Aleph Prieto; Brian H Trieu; Cindy T Dang; Tina Bilousova; Karen H Gylys; Nicole C Berchtold; Gary Lynch; Carl W Cotman
Journal:  J Neurosci       Date:  2016-12-16       Impact factor: 6.167

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 3.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

4.  Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Authors:  Eva Bollen; Daniela Puzzo; Kris Rutten; Lucia Privitera; Jochen De Vry; Tim Vanmierlo; Gunter Kenis; Agostino Palmeri; Rudi D'Hooge; Detlef Balschun; Harry M W Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Neuropsychopharmacology       Date:  2014-05-12       Impact factor: 7.853

5.  Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Authors:  E L Theunissen; P Heckman; E B de Sousa Fernandes Perna; K P C Kuypers; A Sambeth; A Blokland; J Prickaerts; S W Toennes; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2014-07-08       Impact factor: 4.530

Review 6.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

7.  The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans.

Authors:  O A H Reneerkens; A Sambeth; M A Van Duinen; A Blokland; H W M Steinbusch; J Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2012-08-02       Impact factor: 4.530

8.  Tualang Honey Ameliorates Hypoxia-induced Memory Deficits by Reducing Neuronal Damage in the Hippocampus of Adult Male Sprague Dawley Rats.

Authors:  Entesar Yaseen Abdo Qaid; Rahimah Zakaria; Nurul Aiman Mohd Yusof; Shaida Fariza Sulaiman; Nazlahshaniza Shafin; Zahiruddin Othman; Asma Hayati Ahmad; Che Badariah Abd Aziz; Sangu Muthuraju
Journal:  Turk J Pharm Sci       Date:  2020-10-30

9.  Mood and memory function in ovariectomised rats exposed to social instability stress.

Authors:  Badriya Al-Rahbi; Rahimah Zakaria; Zahiruddin Othman; Asma' Hassan; Sangu Muthuraju; Wan Mohd Zahiruddin Wan Mohammad
Journal:  Biomed Res Int       Date:  2013-06-13       Impact factor: 3.411

Review 10.  Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition.

Authors:  Christina Alves Peixoto; Ana Karolina Santana Nunes; Ana Garcia-Osta
Journal:  Mediators Inflamm       Date:  2015-12-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.